Repare Therapeutics (RPTX) News Today $1.37 -0.09 (-6.16%) (As of 10:44 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)December 16 at 1:12 AM | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Given Market Perform Rating at Lifesci CapitalDecember 15 at 3:13 AM | americanbankingnews.comRepere Therapeutics Presents Positive Data from MYTHIC Phase 1 Trial for Gynecologic CancersDecember 15 at 2:35 AM | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Stock, Insider Trading ActivityDecember 15 at 12:34 AM | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock, Short Interest ReportDecember 14, 2024 | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock Quotes, Forecast and News SummaryDecember 14, 2024 | benzinga.comHold Rating on Repare Therapeutics Amid Mixed Trial Results and Anemia ConcernsDecember 14, 2024 | markets.businessinsider.comLifeSci Capital Downgrades Repare Therapeutics (RPTX)December 14, 2024 | msn.comRepare Therapeutics (NASDAQ:RPTX) Receives Market Perform Rating from Lifesci CapitalLifesci Capital reiterated a "market perform" rating on shares of Repare Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comRepare Therapeutics Shares Drop 38% Following Phase 1 Trial ResultsDecember 13, 2024 | ca.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | uk.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | benzinga.comStifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00Stifel Nicolaus decreased their price target on Repare Therapeutics from $9.00 to $4.00 and set a "buy" rating for the company in a report on Friday.December 13, 2024 | marketbeat.comRepare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trialDecember 12, 2024 | markets.businessinsider.comRepare stock tanks 38% after Phase 1 data releaseDecember 12, 2024 | msn.comRepare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialDecember 12, 2024 | businesswire.comRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialDecember 10, 2024 | financialpost.comRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialDecember 10, 2024 | businesswire.comRepare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibNovember 13, 2024 | finance.yahoo.comMorgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)November 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue ForecastsNovember 13, 2024 | finance.yahoo.comRepare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy RatingNovember 11, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRepare Therapeutics: Strategic Clinical Advancements and Promising Data Drive ‘Buy’ RatingNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Reports Q3 2024 Progress and OutlookNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comRepare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical OutcomesOctober 25, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)October 25, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Repare Therapeutics (NASDAQ:RPTX)HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.comRepare Therapeutics Inc.: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialOctober 24, 2024 | finanznachrichten.deRepare Therapeutics presents data from Phase 1 MYTHIC clinical trialOctober 24, 2024 | markets.businessinsider.comRepare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialOctober 23, 2024 | businesswire.comRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase InhibitorOctober 14, 2024 | businesswire.comRepare Therapeutics maintains stock target, positive trial outlookOctober 3, 2024 | uk.investing.comHold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety ConcernsOctober 2, 2024 | markets.businessinsider.comRepare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual MeetingSeptember 30, 2024 | businesswire.comRepare Therapeutics Inc. (NASDAQ:RPTX) Shares Bought by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP raised its position in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 8.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,372,499 shares of the companSeptember 28, 2024 | marketbeat.comRepare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the companySeptember 27, 2024 | finance.yahoo.comBuy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Data and Market PotentialSeptember 24, 2024 | markets.businessinsider.comBSF Enterprise Plc (BSFA.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comRepare Therapeutics (NASDAQ:RPTX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Monday.September 23, 2024 | marketbeat.comRepare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic CancersSeptember 23, 2024 | businesswire.comPiper Sandler Sticks to Its Buy Rating for Repare Therapeutics (RPTX)September 16, 2024 | markets.businessinsider.comAcadian Asset Management LLC Purchases 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)Acadian Asset Management LLC increased its stake in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 212.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 417,929 shares of the company's stock after buying an additional 284,036 shares during the qSeptember 16, 2024 | marketbeat.comRepare Therapeutics Inc. (NASDAQ:RPTX) Forecasted to Post FY2025 Earnings of ($2.79) Per ShareRepare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Investment analysts at Bloom Burton issued their FY2025 earnings per share (EPS) estimates for shares of Repare Therapeutics in a research note issued to investors on Thursday, September 12th. Bloom Burton analyst D. Martin expects that the cSeptember 13, 2024 | marketbeat.comBuy Recommendation: Repare Therapeutics’ Strong Science and Financial Runway Despite SetbackSeptember 13, 2024 | markets.businessinsider.comHold Rating on Repare Therapeutics Awaits Key Clinical Data and Market Potential RealizationSeptember 9, 2024 | markets.businessinsider.comQ3 2024 EPS Estimates for Repare Therapeutics Inc. Decreased by Analyst (NASDAQ:RPTX)Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings estimates for Repare Therapeutics in a research note issued to investors on Wednesday, September 4th. HC Wainwright analyst R. Burns now forecasts that the company will earSeptember 6, 2024 | marketbeat.comBuy Rating on Repare Therapeutics: Strategic Reprioritization and Upcoming Catalysts Bolster Long-Term ProspectsSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Repare Therapeutics (NASDAQ:RPTX)HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Wednesday.September 4, 2024 | marketbeat.com Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available RPTX Media Mentions By Week RPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼0.040.59▲Average Medical News Sentiment RPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼192▲RPTX Articles Average Week Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Foghorn Therapeutics News Larimar Therapeutics News Eledon Pharmaceuticals News Atea Pharmaceuticals News UroGen Pharma News Rezolute News Chimerix News Atyr PHARMA News Mersana Therapeutics News Heron Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
